Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
2006 1
2009 1
2011 1
2012 1
2016 3
2018 1
2019 1
2020 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 82omiej, 20Perek
Page 1
Optimizing identification of Mycoplasma bovis by MALDI-TOF MS.
Bokma J, Pardon B, Van Driessche L, Gille L, Deprez P, Haesebrouck F, Boyen F. Bokma J, et al. Res Vet Sci. 2019 Aug;125:185-188. doi: 10.1016/j.rvsc.2019.06.010. Epub 2019 Jun 20. Res Vet Sci. 2019. PMID: 31252368
Reductive heterocoupling mediated by Cp*2U(2,2'-bpy).
Mohammad A, Cladis DP, Forrest WP, Fanwick PE, Bart SC. Mohammad A, et al. Chem Commun (Camb). 2012 Feb 4;48(11):1671-3. doi: 10.1039/c2cc16200h. Epub 2011 Dec 21. Chem Commun (Camb). 2012. PMID: 22187024
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.
De Leeuw E, Van Damme KFA, Declercq J, Bosteels C, Maes B, Tavernier SJ, Detalle L, Smart T, Glatt S, Debeuf N, Deckers J, Lameire S, Vandecasteele SJ, De Neve N, Demedts IK, Govaerts E, Knoop C, Vanhove K, Moutschen M, Terryn W, Depuydt P, Van Braeckel E, Haerynck F, Hendrickx TCJ, Parrein V, Lalla M, Brittain C, Lambrecht BN. De Leeuw E, et al. Respir Res. 2022 Aug 9;23(1):202. doi: 10.1186/s12931-022-02126-2. Respir Res. 2022. PMID: 35945604 Free PMC article. Clinical Trial.
Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO(2)/FiO(2) below 350 mmHg) were randomized (2:1 ratio) to receive standard of care with or without the C5 inhibitor zilucoplan daily for 14 days, under antibiotic prophylaxis. ...While not …
Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO(2)/FiO(2) below 350 mmHg) were randomized (2:1 ratio) …
Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study.
van der Laan SW, Fall T, Soumaré A, Teumer A, Sedaghat S, Baumert J, Zabaneh D, van Setten J, Isgum I, Galesloot TE, Arpegård J, Amouyel P, Trompet S, Waldenberger M, Dörr M, Magnusson PK, Giedraitis V, Larsson A, Morris AP, Felix JF, Morrison AC, Franceschini N, Bis JC, Kavousi M, O'Donnell C, Drenos F, Tragante V, Munroe PB, Malik R, Dichgans M, Worrall BB, Erdmann J, Nelson CP, Samani NJ, Schunkert H, Marchini J, Patel RS, Hingorani AD, Lind L, Pedersen NL, de Graaf J, Kiemeney LA, Baumeister SE, Franco OH, Hofman A, Uitterlinden AG, Koenig W, Meisinger C, Peters A, Thorand B, Jukema JW, Eriksen BO, Toft I, Wilsgaard T, Onland-Moret NC, van der Schouw YT, Debette S, Kumari M, Svensson P, van der Harst P, Kivimaki M, Keating BJ, Sattar N, Dehghan A, Reiner AP, Ingelsson E, den Ruijter HM, de Bakker PI, Pasterkamp G, Ärnlöv J, Holmes MV, Asselbergs FW. van der Laan SW, et al. J Am Coll Cardiol. 2016 Aug 30;68(9):934-45. doi: 10.1016/j.jacc.2016.05.092. J Am Coll Cardiol. 2016. PMID: 27561768 Free PMC article.
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
Declercq J, Bosteels C, Van Damme K, De Leeuw E, Maes B, Vandecauter A, Vermeersch S, Delporte A, Demeyere B, Vuylsteke M, Lalla M, Smart T, Detalle L, Bouw R, Streffer J, Degeeter T, Vergotte M, Guisez T, Van Braeckel E, Van Der Straeten C, Lambrecht BN. Declercq J, et al. Trials. 2020 Nov 19;21(1):934. doi: 10.1186/s13063-020-04884-0. Trials. 2020. PMID: 33213529 Free PMC article. Clinical Trial.
OBJECTIVES: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. ...
OBJECTIVES: Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote …
12 results